Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: A decision analysis

被引:16
作者
Ng, AK
Weeks, JC
Mauch, PM
Kuntz, KM
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1200/JCO.1999.17.1.241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To perform a decision analysis that compared the life expectancy and quality-adjusted life expectancy of early-stage, favorable-prognosis Hodgkin's disease (HD) managed with and without staging laparotomy, incorporating data on treatment outcomes of HD in the modern era. Methods: We constructed a decision-analytic model to compare laparotomy versus no laparotomy staging for a hypothetical cohort of 25-year-old patients with clinical stages I and II, favorable-prognosis HD. Markov models were used to simulate the lifetime clinical course of patients, whose prognosis depended on the true pathologic stage and initial treatment. The baseline probability estimates used in the model were derived from results of published studies. Quality-of-life adjustments for procedures and treatments, as well as the various long-term health states, were incorporated. Results: The life expectancy was 36.67 years for the laparotomy strategy and 35.92 years for no laparotomy, yielding a net expected benefit of 0.75 years for laparotomy staging, The corresponding quality-adjusted life expectancies for the two strategies were 35.97 and 35.38 quality-adjusted life years (QALYs), respectively, resulting in a net expected benefit of laparotomy staging of 0.59 QALYs. Sensitivity analysis showed that the decision of laparotomy versus no laparotomy was most heavily influenced by the quality-of-life weight assigned to the postlaparotomy state. Conclusion: Our model predicted that on average, for a 25-year-old patient, proceeding with staging laparotomy resulted in a gain in life expectancy of 9 months, or 7 quality-adjusted months, These results suggest that a role remains for surgical staging in the management of early-stage HD. J Clin Oncol 17:241-252, (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:241 / 252
页数:12
相关论文
共 86 条
[1]   A RANDOMIZED STUDY OF ADJUVANT MVPP CHEMOTHERAPY AFTER MANTLE RADIOTHERAPY IN PATHOLOGICALLY STAGED IA-IIB HODGKINS-DISEASE - 10-YEAR FOLLOW-UP [J].
ANDERSON, H ;
CROWTHER, D ;
DEAKIN, DP ;
RYDER, WDJ ;
RADFORD, JA .
ANNALS OF ONCOLOGY, 1991, 2 :49-54
[2]   ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].
ANDERSON, JE ;
LITZOW, MR ;
APPELBAUM, FR ;
SCHOCH, G ;
FISHER, LD ;
BUCKNER, CD ;
PETERSEN, FB ;
CRAWFORD, SW ;
PRESS, OW ;
SANDERS, JE ;
BENSINGER, WI ;
MARTIN, PJ ;
STORB, R ;
SULLIVAN, KM ;
HANSEN, JA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350
[3]   HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC RESCUE IN HODGKINS-DISEASE - LONG-TERM FOLLOW-UP IN 128 PATIENTS [J].
BIERMAN, PJ ;
BAGIN, RG ;
JAGANNATH, S ;
VOSE, JM ;
SPITZER, G ;
KESSINGER, A ;
DICKE, KA ;
ARMITAGE, JO .
ANNALS OF ONCOLOGY, 1993, 4 (09) :767-773
[4]   2ND SOLID TUMORS AND LEUKEMIA AFTER TREATMENT FOR HODGKINS-DISEASE - AN ANALYSIS OF 1121 PATIENTS FROM A SINGLE INSTITUTION [J].
BITI, G ;
CELLAI, E ;
MAGRINI, SM ;
PAPI, MG ;
PONTICELLI, P ;
BODDI, V .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01) :25-31
[5]   EXTENDED-FIELD RADIOTHERAPY IS SUPERIOR TO MOPP CHEMOTHERAPY FOR THE TREATMENT OF PATHOLOGICAL STAGE-I-IIA HODGKINS-DISEASE - 8-YEAR UPDATE OF AN ITALIAN PROSPECTIVE RANDOMIZED STUDY [J].
BITI, GP ;
CIMINO, G ;
CARTONI, C ;
MAGRINI, SM ;
ANSELMO, AP ;
ENRICI, RM ;
BELLESI, GP ;
BOSI, A ;
PAPA, G ;
GIANNARELLI, D ;
PONTICELLI, P ;
PAPI, MG ;
FERRINI, PLR ;
BIAGINI, C ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :378-382
[6]   LATE RELAPSE IN EARLY-STAGE HODGKINS-DISEASE PATIENTS ENROLLED ON EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PROTOCOLS [J].
BODIS, S ;
HENRYAMAR, M ;
BOSQ, J ;
BURGERS, JMV ;
MELLINK, WAM ;
DIETRICH, PY ;
DUPOUY, N ;
NOORDIJK, EM ;
RAEMAEKERS, JMM ;
THOMAS, J ;
EGHBALI, H ;
REGNIER, R ;
TANGUY, A ;
VEDONCK, L ;
MICHEL, J ;
ZITTOUN, R ;
KERKHOFS, H ;
HAYAT, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :225-232
[7]  
BONADONNA G, 1985, CANCER SURV, V4, P439
[8]   SALVAGE RADIOTHERAPY IN RECURRENT HODGKINS-DISEASE [J].
BRADA, M ;
EELES, R ;
ASHLEY, S ;
NICHOLS, J ;
HORWICH, A .
ANNALS OF ONCOLOGY, 1992, 3 (02) :131-135
[9]  
BROGADIR S, 1978, AM J MED, V65, P429
[10]   CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].
CANELLOS, GP ;
ANDERSON, JR ;
PROPERT, KJ ;
NISSEN, N ;
COOPER, MR ;
HENDERSON, ES ;
GREEN, MR ;
GOTTLIEB, A ;
PETERSON, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484